Three States Sue to Block Cannabis Rescheduling: Inside the Schedule III Challenge

The legal fight over federal cannabis rescheduling escalated this month as three state attorneys general filed a petition in federal court to undo the Justice Department's move shifting state-licensed medical marijuana to Schedule III. The challenge, brought by the attorneys general of Nebraska, Indiana, and Louisiana, lands at the most consequential moment for cannabis policy in years — just weeks before a federal hearing that could decide whether rescheduling expands further. For anyone following marijuana rescheduling in 2026, this is the case to watch.

The petition, filed May 22 in the U.S. Court of Appeals for the District of Columbia Circuit, argues that Acting Attorney General Todd Blanche's April 23 final order was both procedurally defective and a violation of international drug-control obligations. It marks the first coordinated, multi-state legal effort to roll back the partial rescheduling that took effect this spring.

What the Rescheduling Order Actually Did

To understand the lawsuit, it helps to be precise about what changed in April. The Justice Department and the Drug Enforcement Administration issued an order placing two narrow categories of cannabis into Schedule III of the Controlled Substances Act: FDA-approved products containing marijuana, and marijuana products regulated under a state medical cannabis license. Everything else — including all adult-use, recreational marijuana — remained squarely in Schedule I.

That distinction matters enormously. Schedule III is reserved for substances with accepted medical use and moderate-to-low potential for dependence, sitting alongside drugs like ketamine and anabolic steroids. By moving state-licensed medical cannabis there, the order opened the door to two practical consequences operators had wanted for years.

The first was tax relief. Section 280E of the Internal Revenue Code bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary expenses. Lifting state-licensed medical marijuana out of Schedule I means those licensees are no longer subject to 280E's punishing deduction disallowance — a change worth millions to multi-state operators. The second was research: rescheduling was framed around President Trump's December 2025 executive order on expanding medical marijuana and cannabidiol research, easing some of the federal restrictions that have long made cannabis science difficult to conduct.

The order also created an expedited DEA registration pathway, letting entities that already hold state medical marijuana licenses submit those credentials as conclusive evidence of state authorization when applying for federal registration.

The Legal Arguments Against the Order

The three states' petition does not argue that cannabis should never be rescheduled. Instead, it attacks how the rescheduling was carried out. The filing contends that the agency action fails to comply with federal law, was improperly promulgated and procedurally improper, exceeds the agency's statutory authority, and is "arbitrary, capricious, an abuse of discretion, and not in accordance with law" — the standard language used to challenge federal rules under the Administrative Procedure Act.

At the center of the complaint is the claim that the administration circumvented standard rulemaking. Ordinarily, rescheduling a controlled substance involves a formal process that includes public notice and a comment period during which stakeholders can weigh in. The states argue that the expedited order skipped or shortchanged those steps, depriving the public of the chance to be heard on a significant policy shift.

The petition raises a second, less common argument: that reclassifying marijuana may conflict with a 1967 international treaty governing the handling of narcotics. International drug-control treaties have historically been cited as a constraint on how far the United States can move cannabis within its own scheduling system, and the states are leaning on that framework to argue the order exceeded what federal law permits.

A Consolidated Fight With Familiar Opponents

The states are not litigating alone. The D.C. Circuit consolidated their complaint with a separate suit filed earlier by Smart Approaches to Marijuana, or SAM, the prohibitionist advocacy group that has opposed legalization efforts at nearly every turn. That consolidation means the court will weigh the procedural and treaty-based objections alongside SAM's challenge in a single proceeding.

The lineup is notable. Indiana Attorney General Todd Rokita had already signaled his intent to block the federal shift, and the May filing folds Indiana into a broader coalition with Nebraska and Louisiana — two states whose own cannabis programs remain limited or nascent. Their participation underscores how the rescheduling fight is being driven as much by states resistant to liberalization as by any single federal actor.

For the cannabis industry, the consolidation is a double-edged development. On one hand, it concentrates the opposition into one case rather than scattering it across multiple courts. On the other, it gives organized prohibitionist interests a high-profile vehicle to argue that the entire rescheduling process was legally flawed.

Why the Timing Matters: The June 29 Hearing

The lawsuit arrives at a pivotal juncture. A separate DEA hearing is scheduled to begin June 29, 2026, to evaluate broader changes to marijuana's federal status — potentially extending rescheduling beyond the narrow categories covered by the April order. That hearing is set to conclude no later than July 15, giving the proceeding an unusually compressed timeline.

So two tracks are now running at once. In one, the DEA is moving toward potentially wider rescheduling through a formal hearing. In the other, three states and SAM are asking a federal appeals court to unwind the rescheduling that has already taken effect. The outcomes are interrelated: a ruling that the April order was procedurally improper could cast a long shadow over any expansion that emerges from the summer hearing.

For operators who have already begun restructuring their tax positions around the end of 280E exposure, the litigation introduces real uncertainty. A favorable court ruling for the states would not necessarily reverse the policy outright, but it could force the administration back to a slower, more formal rulemaking process — delaying the benefits that licensees have been counting on.

What This Means Going Forward

It is worth keeping expectations grounded. Procedural challenges to federal scheduling decisions are common, and they do not always succeed; courts often give agencies substantial deference on how they manage controlled-substance classifications. The treaty argument, while attention-grabbing, faces a steep climb, since domestic scheduling and international obligations have coexisted through previous policy shifts.

Still, the case represents the most serious organized attempt yet to halt the 2026 rescheduling, and its trajectory will signal how durable the Schedule III move really is. If the court moves quickly, a decision could come before or around the same window as the DEA's summer hearing, compounding the stakes. If it drags, the legal cloud could hang over the industry for months even as the practical benefits of rescheduling continue to roll out.

For now, state-licensed medical marijuana remains in Schedule III, the expedited registration pathway is open, and the 280E relief stands. But the three-state petition is a reminder that in cannabis policy, almost nothing is settled until the courts have spoken.

Key Takeaways

• Nebraska, Indiana, and Louisiana filed a petition May 22 in the D.C. Circuit to block the federal rescheduling of state-licensed medical marijuana to Schedule III.
• The lawsuit argues the April 23 order was procedurally improper, exceeded statutory authority, and may violate a 1967 international drug treaty.
• The court consolidated the states' challenge with a separate suit from the prohibitionist group Smart Approaches to Marijuana.
• A separate DEA hearing on broader rescheduling begins June 29 and must conclude by July 15, making the next several weeks decisive.
• A ruling against the order could force a slower formal rulemaking and delay the 280E tax relief operators are counting on.

Explore cannabis news, find dispensaries, and join the community at Budpedia.